Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.
Stewart AK et al. N Engl J Med. 2014 Dec 6. [Epub ahead of print].
Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, inmultiple myeloma patients.
Carmon L et al. Br J Haematol. 2014 Dec 11. doi: 10.1111/bjh.13245. [Epub ahead of print].
The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD et al. Expert Opin Investig Drugs. 2014 Dec 13:1-11. [Epub ahead of print].
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Andreu-Vieyra CV et al. Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614.
Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure.
Qi J et al. Cold Spring Harb Perspect Biol. 2014 Dec 1;6(12). pii: a018663. doi: 10.1101/cshperspect.a018663.